Literature DB >> 2503274

Intravenous immune globulin impairs anti-bacterial defences of a cyclophosphamide-treated host.

A S Cross1, G Siegel, W R Byrne, M Trautmann, D S Finbloom.   

Abstract

Since intravenous immune globulin (i.v.IG) could impair the clearance of autologous IgG-coated erythrocytes by the reticuloendothelial system (RES), we speculated that a patient with leucopenia who died of candida septicaemia following high dose i.v.IG may have had an impairment of his RES function. We therefore studied the ability of intact i.v.IG to impair the clearance of both soluble immune complexes and a relatively avirulent strain of E. coli from the blood of mice made leucopenic with cyclophosphamide. In the presence of leucopenia, 800 micrograms/g i.v.IG prolonged the time to clear 50% of the administered IgG anti-dinitrophenyl immune complex (T1/2) from 2.7 min to 12 min, impaired the clearance of E. coli and lowered the LD50 of the strain five-fold. This impaired clearance of soluble complexes and increased mortality (8/67 versus 37/69, P less than 0.001) following bacterial challenge was present for up to 120 and 60 min, respectively, following the administration of i.v.IG. In contrast, no significant impairment in RES function was noted when 200 micrograms/g i.v.IG was administered to leucopenic mice, or when cyclophosphamide alone was given to mice before challenge with either soluble complexes or bacteria. In addition, no change in LD50 was found when mice were pretreated with 800 micrograms/g i.v.IG alone. These data suggest that high doses of i.v.IG may impair anti-microbial defences of a leucopenic host and thereby convert a relatively avirulent organism into a pathogen.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503274      PMCID: PMC1541841     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Protective antibody to endotoxin core: the emperor's new clothes?

Authors:  E J Ziegler
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

2.  High-dose intravenous immunoglobulin in the management of myasthenia gravis.

Authors:  E L Arsura; A Bick; N G Brunner; T Namba; D Grob
Journal:  Arch Intern Med       Date:  1986-07

3.  Intravenous immune globulin: a cautionary note.

Authors:  A S Cross; B M Alving; J C Sadoff; P Baldwin; H Terebelo; D Tang
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

4.  Treatment of pure red cell aplasia by high dose intravenous immunoglobulins.

Authors:  J P Clauvel; W Vainchenker; A Herrera; K Dellagi; G Vinci; A Tabilio; C Lacombe
Journal:  Br J Haematol       Date:  1983-10       Impact factor: 6.998

5.  Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin.

Authors:  R Kekomäki; G Elfenbein; R Gardner; J Graham-Pole; P Mehta; S Gross
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

6.  High-dose intravenous IgG in adults with autoimmune thrombocytopenia.

Authors:  A C Newland; J G Treleaven; R M Minchinton; A H Waters
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

7.  Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura.

Authors:  J B Bussel; R P Kimberly; R D Inman; I Schulman; C Cunningham-Rundles; N Cheung; E M Smithwick; J O'Malley; S Barandun; M W Hilgartner
Journal:  Blood       Date:  1983-08       Impact factor: 22.113

8.  Intravenous immune globulin therapy. Treatment of a patient with severe immunodeficiency, chronic malabsorption, and fulminant septicemia.

Authors:  E B Gonzalez; B G Guernsey; N B Ingrim; Y Ichikawa; J C Daniels
Journal:  Arch Intern Med       Date:  1985-05

9.  Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease.

Authors:  C M Roifman; H M Lederman; S Lavi; L D Stein; H Levison; E W Gelfand
Journal:  Am J Med       Date:  1985-08       Impact factor: 4.965

10.  Intravenous administration of human IgG to newborn infants: changes in serum antibody levels to group B streptococci.

Authors:  K K Christensen; P Christensen; H U Bucher; G Duc; C H Kind; D Mieth; B Müller; R A Seger
Journal:  Eur J Pediatr       Date:  1984-12       Impact factor: 3.183

View more
  3 in total

Review 1.  Intravenous immunoglobulin for secondary immunodeficiency.

Authors:  P L Yap
Journal:  Blut       Date:  1990-01

2.  Structural insights into lipoprotein N-acylation by Escherichia coli apolipoprotein N-acyltransferase.

Authors:  Cameron L Noland; Michele D Kattke; Jingyu Diao; Susan L Gloor; Homer Pantua; Mike Reichelt; Anand K Katakam; Donghong Yan; Jing Kang; Inna Zilberleyb; Min Xu; Sharookh B Kapadia; Jeremy M Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-11       Impact factor: 11.205

3.  Peptidoglycan Association of Murein Lipoprotein Is Required for KpsD-Dependent Group 2 Capsular Polysaccharide Expression and Serum Resistance in a Uropathogenic Escherichia coli Isolate.

Authors:  Jingyu Diao; Catrien Bouwman; Donghong Yan; Jing Kang; Anand K Katakam; Peter Liu; Homer Pantua; Alexander R Abbas; Nicholas N Nickerson; Cary Austin; Mike Reichelt; Wendy Sandoval; Min Xu; Chris Whitfield; Sharookh B Kapadia
Journal:  MBio       Date:  2017-05-23       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.